Skip to content

FDA approves J&J Ebola test

A Johnson & Johnson diagnostic test that can detect the Ebola virus has been authorized by the U.S. Food and Drug Administration for emergency use when there is a suspected outbreak.

A Johnson & Johnson diagnostic test that can detect the Ebola virus has been authorized by the U.S. Food and Drug Administration for emergency use when there is a suspected outbreak.

The test, developed by J&J subsidiary Janssen Pharmaceutica and partner Biocartis NV in Belgium, detects the Ebola strain that caused more than 11,000 deaths in West Africa in 2014.

Using only a few drops of blood, the test can distinguish Ebola from other fevers, such as malaria, in 100 minutes, said Janssen medical director Theresa Pattery. J&J is also developing an Ebola vaccine.

Johnson & Johnson, based in New Brunswick, N.J., has 250 companies worldwide including McNeil Consumer Healthcare in Fort Washington and Synthes medical device maker in West Chester.

"Across Johnson & Johnson, we are mobilizing our resources and expertise to help prevent another outbreak of Ebola," said Janssen's chief medical officer Jorge Villacian.

lloyd@phillynews.com

215-854-2831

@LoydLinda